UBS Maintains Neutral on GoodRx Holdings, Raises Price Target to $3.75

GoodRx Holdings, Inc. Class A

GoodRx Holdings, Inc. Class A

GDRX

0.00

UBS analyst Kevin Caliendo maintains GoodRx Holdings (NASDAQ: GDRX) with a Neutral and raises the price target from $2.5 to $3.75.